Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer

Clinical Cancer Research

Volumn 15, Issue 7, 2009, Pages 2361-2372

  Pernas, Francisco G ^a   Allen, Clint T ^a   Winters, Mary E ^b   Yan, Bin ^a   Friedman, Jay ^a   Dabir, Bhavana ^b   Saigal, Kunal ^a   Mundinger, Gerhard S ^b   Xu, Xiaojiang ^c   Morris, John C ^b   Calvo, Katherine R ^b   Van Waes, Carter ^a   Chen, Zhong ^a  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BIOLOGICAL MARKER; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PACLITAXEL; PROTEIN KINASE B; STAT3 PROTEIN;

ADVANCED CANCER; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA SEQUENCE; DOSE RESPONSE; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; REVERSE PHASE PROTEIN MICROARRAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; CLINICAL TRIALS, PHASE I AS TOPIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDERMAL GROWTH FACTOR; HEAD AND NECK NEOPLASMS; HUMANS; INHIBITORY CONCENTRATION 50; NF-KAPPA B; PHOSPHORYLATION; PROTEIN ARRAY ANALYSIS; PROTEIN KINASE INHIBITORS; PROTEOMICS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 65349130024     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1011     Document Type: Article

References (50)

1. Thelemann A, Petti F, Griffin G, et al. Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells. Mol Cell Proteomics 2005;4:356-76.
2. Santini J, Formento JL, Francoual M, et al. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991;13: 132-9.
3. Dassonville O, Formento JL, Francoual M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993;11:1873-8.
4. Rogers SJ, Harrington KJ, Rhys-Evans P, O-Charoenrat P, Eccles SA. Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev 2005;24:47-69.
5. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006;24:2666-72.
6. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor- tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002;20:2240-50.
7. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-302.
8. Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004;96:1133-41.
9. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small- cell lung cancer. J Clin Oncol 2006;24:5034-42.
10. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006;12: 5064-73.
11. Cohen EE, Rosen F, StadlerWM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21:1980-7.
12. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
13. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from ''never smokers''and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA2004;101:13306-11.
14. Paez JG,Janne PA,Lee JC,et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science New York NY 2004;304: 1497-500.
15. Mitsudomi T, KosakaT, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative re- currence. J Clin Oncol 2005;23:2513-20.
16. MitsudomiT, KosakaT,YatabeY Biological and clinical implications of EGFR mutations in lung cancer. Int JClin Oncol Japan Soc Clin Oncol 2006;11:190-8.
17. Temam S, Kawaguchi H, El-NaggarAK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007; 25:2164-70.
18. Cohen EE, Lingen MW, Martin LE, et al. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 2005;11:8105-8.
19. Loeffler-Ragg J, Witsch-Baumgartner M,Tzankov A, et al. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squa- mous cell carcinoma. Eur J Cancer 2006;42:109-11.
20. Lee JW, SoungYH, Kim SY, et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11:2879-82.
21. Calvo KR, Liotta LA, Petricoin EF. Clinical proteo- mics: from biomarker discovery and cell signaling profiles to individualized personal therapy. Biosci Rep 2005;25:107-25.
22. Hingorani SR, Petricoin EF, Maitra A, et al. Prein- vasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4: 437 -50.
23. YanB, Yang X, Lee TL,et al. Genome-wide identification of novel expression signatures reveal distinct patterns and prevalence of binding motifsforp53,nu- clear factor-κB and other signal transcription factors in head and neck squamous cell carcinoma. Genome Biol 2007;8:R78.
24. GuD,ScaringeWA,LiK,etal.Databaseofsomatic mutations in EGFR with analyses revealing indel hot- spots but no smoking-associated signature. Hum Mutat 2007;28:760-70.
25. Worden B, Yang XP, LeeTL, et al. Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma. Cancer Res 2005;65:7071 -80.
26. BancroftCC,ChenZ,YehJ,etal.Effectsofpharma- cologicantagonists of epidermal growth factorrecep- tor, PI3K and MEK signal kinases on NF-κBand AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 2002;99:538-48.
27. LeeTL,Yeh J,VanWaesC, Chen Z. Epigenetic modification of SOCS-1differentially regulates STAT3 activation in response to interleukin- 6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol Cancer Ther 2006;5:8-19.
28. DongG, ChenZ, LiZY, YehNT, Bancroft CC, Van Waes C. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. CancerRes 2001;61:5911 -8.
29. HongSH,OndreyFG,AvisIM,etal.Cyclooxyge- nase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation? FASEB J 2000;14:1499-507.
30. Lee TL, Yang XP, Yan B, et al. A novel nuclear factor-κB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clin Cancer Res 2007; 13:5680-91.
31. LeeTL,Yeh J, Friedman J, et al. A signal network involving coactivated NF- κB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. IntJ Cancer 2008;122:1987-98.
32. MukoharaT, Engelman JA, Hanna NH, et al. Differential effects of gefitinib and cetuximab on non- small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 2005;97: 1185-94.
33. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev2004;18:2195-224.
34. Sunwoo JB, Herscher LL, Kroog GS, et al. Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. J Clin Oncol 2001; 19:800-11.
35. Pomerantz RG, GrandisJR. The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy. Semin Oncol 2004;31:734-43.
36. Boerner JL, Biscardi JS, Silva CM, Parsons SJ. Transactivating agonists of the EGF receptor require Tyr845 phosphorylation forinduction of DNAsynthe- sis. Mol Carcinog 2005;44:262-73.
37. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene 2003;22:8983-98.
38. She QB, Solit DB,Ye Q, O'Reilly KE, Lobo J, Rosen N. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN- deficient tumor cells. Cancer Cell 2005;8:287-97.
39. Zebisch A, Czernilofsky AP, Keri G, Smigelskaite J, Sill H,TroppmairJ. Signaling through RAS-RAF-MEK- ERK: from basics to bedside. Curr Med Chem 2007; 14:601 -23.
40. OkabeT,Okamoto I,TamuraK,etal. Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res 2007;67:2046-53.
41. Noro R, GemmaA, KosaihiraS, et al. Gefitinib (IRE- SSA) sensitive lung cancer cell lines show phosphor- ylation of Akt withoutlig and stimulation. BMC Cancer 2006;6:277.
42. Batra SK, Castelino-Prabhu S,Wikstrand CJ, et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 1995;6:1251 -9.
43. Huang HS, Nagane M, Klingbeil CK, et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 1997;272:2927-35.
44. Okamoto I, Kenyon LC, Emlet DR, et al. Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci 2003;94:50-6.
45. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 2006;12:7242-51.
46. Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind JS. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 2003;63:2948-56.
47. Quesnelle KM, Boehm AL, Grandis JR. STAT- mediated EGFR signaling in cancer. J Cell Biochem 2007;102:311 -9.
48. 48.VanWaesC. Nuclear factor-κB in development,pre- vention, and therapy of cancer. Clin Cancer Res 2007; 13:1076-82.
49. An J, Rettig MB. Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Mol Cancer Ther 2007;6:61 -9.
50. Nishizuka S, Charboneau L,Young L, et al. Proteo- micprofilingoftheNCI- 60cancer cell linesusing new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A2003;100:14229-34.